A country-by-country map of official medicine regulators, approval records, trial context and analytical evidence. This hub does not provide prices, vendor rankings, procurement routes or region-wide legal conclusions.
Quick answer
Start with the jurisdiction and the exact question. Medicine registration, controlled status, import requirements, clinical-trial status and analytical documentation come from different records. A result in one lane should not be used as proof in another.
A medicine record in Saudi Arabia does not establish status in Qatar, Lebanon or the UAE.
Claimed research intent does not replace registration, schedule, customs or institutional review.
These pages explain regulation, approval status, trials and analytical records without directing readers toward sellers or transactions.
What public UAE medicine and import sources establish, and why no blanket RUO exemption can be inferred.
Current investigational status, sponsor filing plan and the difference between trial milestones and authorization.
Current registry status and UAE-specific trial context without implying access outside authorized research.
How to read HPLC, identity and sterility fields and where a Certificate of Analysis stops.
Tirzepatide authorization, prescribing status, mechanism and clinical-evidence context without price or clinic routing.
Dated regulatory status for investigational obesity and metabolic compounds.
These portals are starting points, not substitutes for an exact compound-level search or qualified advice.
| Jurisdiction | Official layer | Use it for |
|---|---|---|
| UAE | UAE drugs and controlled medicines; MoHAP; EDE | Medicine, controlled-medicine and permit context |
| Saudi Arabia | SFDA and new-drug approvals | National authorization and regulatory updates |
| Qatar | MOPH Pharmacy and Drug Control; DHP | Medicine-registration and practitioner oversight |
| Lebanon | MOPH National Drugs Database | Registered-medicine records |
A sponsor filing, FDA action or foreign authorization does not automatically create a UAE, Saudi, Qatari or Lebanese authorization.
A ClinicalTrials.gov entry documents a study. It does not establish market authorization, routine prescribing or pharmacy status.
A batch report documents the named tests for the identified sample. It cannot determine controlled status, import permission or lawful use.
Research-use labelling states claimed intent but does not override medicine, customs or controlled-substance rules.
It organizes official regulator portals and Remy evidence references for the UAE, Saudi Arabia, Qatar and Lebanon. It does not rank sellers, compare prices, provide procurement routes, or make a single legal conclusion for the whole region.
No. Each jurisdiction has its own medicine regulator, registration records, controlled-substance schedules, customs rules and professional oversight. A status in one country should not be assumed to apply in another.
No. An RUO label records claimed intent but does not create approval, import permission or a region-wide exemption. The exact compound, intended use, presentation and jurisdiction must be checked against current primary sources.
Retatrutide remains investigational and no UAE or GCC marketing authorization was located for this update. Trial activity and analytical batch records do not create a prescription, pharmacy or human-use pathway.
No. A Certificate of Analysis can report test results for an identified sample. Medicine approval, legal import, controlled status and clinical evidence are separate questions.
Use MoHAP and EDE materials for the UAE, SFDA records for Saudi Arabia, MOPH and DHP for Qatar, and the MOPH National Drugs Database for Lebanon. Verify the exact compound and current record rather than relying on a regional summary.